Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: A systematic review

European Urology

Volumn 60, Issue 3, 2011, Pages 493-500

  Van Den Bosch, Sven ^a   Witjes, J Alfred ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bladder cancer; High risk; Long term; Non muscle invasive bladder cancer; Progression; Survival; Systematic review; Urothelial carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT;

BLADDER CANCER; BLADDER SURGERY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER PATIENT; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CARCINOMA IN SITU; COCHRANE LIBRARY; CYSTECTOMY; FOLLOW UP; HUMAN; LONG TERM CARE; MEDLINE; NON MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; SYSTEMATIC REVIEW; TRANSURETHRAL RESECTION; TRANSURETHRAL RESECTION OF THE BLADDER TUMOR;

CARCINOMA; CYSTECTOMY; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; HUMANS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 79960992110     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.05.045     Document Type: Review

References (45)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765-81.
2. Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005;66:4-34. (Pubitemid 43049607)
3. Sylvester RJ, van der Meijden APM, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-77.
4. Bohle A, Bock PR. Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004;63:682-6. (Pubitemid 38479409)
5. Sylvester RJ, Brausi MA, Kirkels WJ, et al., EORTC Genito-Urinary Tract Cancer Group. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010;57:766-73.
6. Malmström P-U, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247-56.
7. Raj GV, Herr H, Serio AM, et al. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol 2007;177:1283-6. (Pubitemid 46435978)
8. Hautmann RE, Volkmer BG, Gust K. Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3). World J Urol 2009;27:347-51.
9. Lambert EH, Pierorazio PM, Olsson CA, Benson MC, McKiernan JM, Poon S. The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy. BJU Int 2007;100:33-6. (Pubitemid 46878562)
10. Vaidya A, Soloway MS, Hawke C, Tiguert R, Civantos F. De novo muscle invasive bladder cancer: is there a change in trend? J Urol 2001;165:47-50.
11. Schrier BP, Hollander MP, van Rhijn BWG, Kiemeney LALM, Witjes JA. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol 2004;45:292-6. (Pubitemid 38221401)
12. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
13. Park J, Song C, Hong JH, et al. Prognostic significance of non-papillary tumor morphology as a predictor of cancer progression and survival in patients with primary T1G3 bladder cancer. World J Urol 2009;27:277-83.
14. Lerner SP, Tangen CM, Sucharew H, Wood D, Crawford ED. Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. Urol Oncol 2009;27:155-9.
15. Iida S, Kondo T, Kobayashi H, Hashimoto Y, Goya N, Tanabe K. Clinical outcome of high-grade non-muscle-invasive bladder cancer: a long-term single center experience. Int J Urol 2009;16:287-92.
16. Boorjian SA, Zhu F, Herr HW. The effect of gender on response to bacillus Calmette-Guerin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder. BJU Int 2010;106:357-61.
17. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:1964-70.
18. Lee CT, Dunn RL, Ingold C, Montie JE, Wood Jr DP. Early-stage bladder cancer surveillance does not improve survival if high-risk patients are permitted to progress to muscle invasion. Urology 2007;69:1068-72. (Pubitemid 46891598)
19. Ferreira U, Matheus WE, Nardi PR, et al. Primary invasive versus progressive invasive transitional cell bladder cancer: multicentric study of overall survival rate. Urol Int 2007;79:200-3. (Pubitemid 47586926)
20. Thalmann GN, Markwalder R, Shahin O, Burkhard FC, Hochreiter WW, Studer UE. Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy? J Urol 2004;172:70-5.
21. Denzinger S, Fritsche H-M, Otto W, Blana A, Wieland W-F, Burger M. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? Eur Urol 2008;53:146-52.
22. Solsona E, Iborra I, Rubio J, Casanova J, Almenar S. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour. BJU Int 2004;94:1258-62. (Pubitemid 40052089)
23. Dalbagni G, Vora K, Kaag M, et al. Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. Eur Urol 2009;56:903-10.
24. Fritsche H-M, Burger M, Svatek RS, et al. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol 2010;57:300-9.
25. Palou J, Algaba F, Vera I, Rodriguez O, Villavicencio H, Sanchez-Carbayo M. Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with non-maintenance bacillus Calmette-Guérin. Eur Urol 2009;56:829-36.
26. Fernandez-Gomez J, Solsona E, Unda M, et al. for the Club Urológico Español de Tratamiento Oncológico (CUETO). Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 2008;53:992-1002.
27. Vrooman OP, Witjes JA. Molecular markers for detection, surveillance and prognostication of bladder cancer. Int J Urol 2009;16:234-43.
28. Bryan RT, Zeegers MP, James ND, Wallace DM, Cheng KK. Biomarkers in bladder cancer. BJU Int 2010;105:608-13.
29. Hollenbeck BK, Ye Z, Dunn RL, Montie JE, Birkmeyer JD. Provider treatment intensity and outcomes for patients with early-stage bladder cancer. J Natl Cancer Inst 2009;101:571-80.
30. Di Stasi SM, Giannantoni A, Giurioli A, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 2006;7:43-51. (Pubitemid 43025392)
31. Dalbagni G, Parekh DJ, Ben-Porat L, Potenzoni M, Herr HW, Reuter VE. Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder. BJU Int 2007;99:281-5. (Pubitemid 46103104)
32. Kamel MH, Daly PJ, Khan MF, Kay EW, O'Kelly P, Hickey DP. Survival and progression in high grade tumour subset of G2 and G3 pT1 bladder transitional cell carcinoma. Eur J Surg Oncol 2006;32:1139-43. (Pubitemid 44774388)
33. Denzinger S, Otto W, Fritsche HM, et al. Bladder sparing approach for initial T1G3 bladder cancer: do multifocality, size of tumor or concomitant carcinoma in situ matter? A long-term analysis of 132 patients. Int J Urol 2007;14:995-9. (Pubitemid 47621840)
34. Chade DC, Shariat SF, Adamy A, et al. Clinical outcome of primary versus secondary bladder carcinoma in situ. J Urol 2010;184:464-9.
35. Alkhateeb SS, van Rhijn BW, Finelli A, et al. Nonprimary pT1 non-muscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors. J Urol 2010;184:81-6.
36. Gardmark T, Jahnson S, Wahlquist R, Wijkstrom H, Malmstrom PU. Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guerin in patients with high-risk bladder cancer. BJU Int 2007;99:817-20. (Pubitemid 46439578)
37. Esuvaranathan K, Chiong E, Thamboo TP, et al. Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha. Cancer 2007;109:1097-105. (Pubitemid 46435388)
38. Gofrit ON, Pode D, Pizov G, et al. The natural history of bladder carcinoma in situ after initial response to bacillus Calmette-Guerin immunotherapy. Urol Oncol 2009;27:258-62.
39. Zieger K, Wiuf C, Jensen KM, Ørntoft TF, Dyrskjøt L. Chromosomal imbalance in the progression of high-risk non-muscle invasive bladder cancer. BMC Cancer 2009;9:149.
40. Moonen PM, van Balken-Ory B, Kiemeney LA, Schalken JA, Witjes JA. Prognostic value of p53 for high risk superficial bladder cancer with long-term followup. J Urol 2007;177:80-3. (Pubitemid 44879442)
41. Margel D, Tal R, Golan S, Kedar D, Engelstein D, Baniel J. Long-term follow-up of patients with stage T1 high-grade transitional cell carcinoma managed by bacille Calmette-Guerin immunotherapy. Urology 2007;69:78-82. (Pubitemid 46161685)
42. Queipo-Zaragoza JA, Ruiz-Cerda JL, Vera-Donoso CD, Vera-Sempere F, Budia-Alba A, Jimenez-Cruz JF. Prognostic value of p53, Ki-67, microstaging and microvessel density in pT1G3 bladder tumors: creation of risk groups for progression. Scand J Urol Nephrol 2007;41:283-9. (Pubitemid 47357188)
43. Serretta V, Ruggirello A, Dispensa N, Allegro R, Aragona F, Melloni D. Multiplicity and history have a detrimental effect on survival of patients with T1G3 bladder tumors selected for conservative treatment. J Urol 2008;180:886-90.
44. van Rhijn BW, van der Kwast TH, Kakiashvili DM, et al. Pathological stage review is indicated in primary pT1 bladder cancer. BJU Int 2010;106:206-11.
45. Alvarez-Mugica M, Cebrian V, Fernandez-Gomez JM, Fresno F, Escaf S, Sanchez-Carbayo M. Myopodin methylation is associated with clinical outcome in patients with T1G3 bladder cancer. J Urol 2010;184:1507-13.